Royce & Associates LP Alkermes Plc. Transaction History
Royce & Associates LP
- $10.5 Billion
- Q3 2024
A detailed history of Royce & Associates LP transactions in Alkermes Plc. stock. As of the latest transaction made, Royce & Associates LP holds 67,628 shares of ALKS stock, worth $2.01 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
67,628
Previous 45,272
49.38%
Holding current value
$2.01 Million
Previous $1.09 Million
73.42%
% of portfolio
0.02%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding ALKS
# of Institutions
362Shares Held
181MCall Options Held
175KPut Options Held
96.6K-
Black Rock Inc. New York, NY29.1MShares$863 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA19MShares$563 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD13MShares$385 Million0.04% of portfolio
-
Wellington Management Group LLP Boston, MA12.7MShares$375 Million0.06% of portfolio
-
State Street Corp Boston, MA9.19MShares$272 Million0.01% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $4.87B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...